Loading company
Boston Scientific Corp.
BSX · NYSE · ·
Next earnings: October 28, 2026 · before the open
$43.89-0.5%Sep 29 close
- 1M
- -6.3%
- 6M
- -30.3%
- 1Y
- -55.0%
- 5Y
- -1.3%
BSX · NYSE · ·
Next earnings: October 28, 2026 · before the open
$43.89-0.5%Sep 29 close
Boston Scientific Corp. is scheduled to report next on October 28, 2026, before the open. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $5.4B | $5.1B | +7.53% |
| Profit | $905M | $795M | +13.84% |
| Profit per share | $0.61 | $0.53 | +15.09% |
| Free Cash Flow | $1.3B | $1.1B | +13.29% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our team delivered a solid quarter while continuing to navigate a dynamic environment,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Boston Scientific Corp.’s Item 2.02 8-K filed July 29, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
A short summary of each call — what the quarter showed, what management expects and whether they delivered on what they said last time — with the full transcript underneath.
Source: Yahoo Finance, transcribed by Quartr. Speaker names and roles are as transcribed; analysts are sometimes unnamed.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Call summaries are part of Pro
A two-minute read of every Boston Scientific Corp. earnings call: the numbers that mattered, what management expects, whether they delivered on last quarter’s outlook, and what analysts asked that went unanswered.
See one first on , , or — open to everyone.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.